Ê×Ò³| Â鶹´«Ã½Ó³»­

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

The Alzheimer's Foundation of America (AFA) will be holding a free, virtual continuing medical education (CME) program for physicians on Thursday, September 10th from 12 pm to 2:30 pm (ET). Physicians can register by clicking here.

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).

A systematic review of Alzheimer disease (AD) treatments currently in development demonstrate the progressive emphasis on nonamyloid targets, including candidate treatments addressing for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions.

Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer’s.

The Ê×Ò³| Â鶹´«Ã½Ó³»­ has announced a $6 million commitment from Joy Chambers-Grundy and the late Reg Grundy to establish a center dedicated to research on and the treatment of neurological disorders.

UNLV announced Monday that it has launched a center dedicated to scientific research about brain and neurological diseases such as Alzheimer’s and dementia.